Marty Makary

speaker

939 appearances 6 recordings 5 series first heard Jan 2026 last heard 13 May

Marty Makary’s voice in public audio — every appearance, attributed to the second.

Trend

recordings per month · last 12 months

Recordings per month over the last 12 months — 6 in all, peaking in Jan 2026 with 4.

Appearances

newest first · ▶ plays the moment

All-In with Chamath, Jason, Sacks & Friedberg · Supercharging a New FDA: Marty Makary on Science, Power & Patients · 15 Jan 2026 podcast

Maybe you can respond to some of the criticisms, that it's chaotic, that there's a lot of turmoil.

I've worked at many startups.

I know that when you move fast, things feel, or they may feel too busy, or they may feel like there's too much going on.

It's overwhelming at times, but at the end of the day, progress is what matters.

Maybe you could just comment on some of the reports made by employees that have quit the FDA, left, and provided some comments on how things are going.

Great.

Well, look, let's start with a framing.

The framing is the US versus China.

I want to read this report that came from the Congressional National Security Commission on Emerging Biotechnology.

We're here at a biotech conference, so I figured we could start here because everyone's talking about China and the race against China.

The US, according to this commission, has a three-year window to act to keep up with Chinese innovation and the speed in biotech.

In 2022, Chinese companies were just 5% of licensing deals.

2025, 42%.

And recently, one of the biggest licensing deals ever was 3S Bio, $1.25 billion upfront with a $6 billion total with Pfizer.

China had, 10 years ago, only 50% of published scientific papers to the US.

Today, they're 50% more than the US.

So I just want to walk through your view on US biopharma innovation as it relates to China.

Is there a race?

And if so, what are the priorities for the administration in helping American biotech industry remain competitive?

As you think about those work streams in improving the efficiency, turnaround time, how much can you do this on your own versus how much do you need Congress to act to pass legislation to support those changes?

Showing 401–420 of 939 · page 21 of 47